Clinical trial
Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select…
NCT00292864 · Sunesis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00292864 |
|---|---|
| Title | Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors |
| Official title | Phase 1 Open-Label, Multicenter, Dose-Escalation Clinical Study of the Safety and Tolerability of SNS-032, a Novel Cyclin-Dependent Kinase Inhibitor, Administered to Patients With Select Advanced Solid Tumors |
| Lead sponsor | Sunesis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | SNS-032 Injection |
| Enrollment | 25 |
| Start date | Jan 1, 2006 |
| Completion | Dec 1, 2007 |
| First posted | Feb 16, 2006 |
| Last update posted | Jun 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: